Research use only · Not for human or veterinary use · Not for diagnostic or therapeutic application

Literature

Reading list and
evidence report.

Two working documents: a citation-led reading list across nine topic areas, and an evidence-quality report on compounds most channels skip. Both are written to separate mechanism from proof — what the literature shows, and what it does not.

Reference material for research context only. Nothing here is dosing, preparation or administration guidance, and no part of it describes use of these materials in humans or animals.

Compiled by @ThePepEducator · June 2026

07Reading list

Nine topic areas, sourced to primary literature.

Work through the 'read first' papers in each section. Read the methods before the abstract's claim, and check what the authors themselves say the study cannot prove.

Read first

Foundational or highest-quality evidence

Read second

Important supplementary context

Read third

Useful background or niche depth

01

Retatrutide & GLP-1 Class Mechanisms

GLP-1 / Metabolic

Retatrutide (LY3437943) is the most clinically advanced triple agonist currently in Phase III. Understanding the mechanistic progression from semaglutide (single) → tirzepatide (dual) → retatrutide (triple) is foundational to credible content in this category. These papers give you the structural, pharmacological, and clinical data you need.

  1. Nature / PMC (Free)
    Read first

    Cryo-EM structural data. How retatrutide physically binds all three receptors. Essential for mechanistic deep-dives.

  2. Nature Medicine
    Read first

    Phase 2a RCT data for liver fat reduction. Demonstrates GCGR-specific hepatic benefit over semaglutide.

  3. ScienceDirect
    Read second

    Good narrative review covering Phase II weight loss data (24.2% at 48 weeks) and cardiovascular potential.

  4. Lancet / EClinicalMedicine
    Read second

    Maps receptor targets to weight loss outcomes across drug classes. Strong framing for content comparisons.

  5. NEJM
    Read first

    The primary Phase 2 trial. 24.2% weight loss at 48 weeks, 12mg dose. This is the paper everything else cites.

02

BPC-157 — Mechanisms & Musculoskeletal

Tissue Repair

BPC-157 has the largest preclinical evidence base of any research peptide in common use. The key mechanistic pathways are VEGFR2/Akt/eNOS (angiogenesis), FAK-paxillin (fibroblast migration), and GHR upregulation (potentiating GH effects). The critical gap is the near-absence of human RCTs — knowing this distinction is what separates credible education from bro-science.

  1. PubMed (Free)
    Read first

    Best current narrative review. Covers VEGFR2-Akt-eNOS axis, ERK1/2 signaling, and honestly flags that only 3 human pilot studies exist.

  2. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review

    Vasireddi, Hahamyan, Salata, Calcei, Voos et al. · SAGE Journals, 2025

    SAGE Journals
    Read first

    Systematic review of 36 studies (1993–2024). Covers fractures, tendon ruptures, ligament tears, muscle tears. Most rigorous current synthesis.

  3. MDPI (Open Access)
    Read second

    Broad mechanism overview including neurotransmitter interactions. Patent review angle gives industry context.

  4. The promoting effect of BPC 157 on tendon healing: tendon outgrowth, cell survival, and migration

    Chang, Tsai, Lin, Hsu, Pang Su · Journal of Applied Physiology, 2011

    APS (Free)
    Read second

    Foundational tendon fibroblast study. Still the most cited for tendon outgrowth mechanism.

  5. PMC (Free)
    Read third

    GHR upregulation mechanism — explains why BPC-157 may potentiate GH effects. Useful for advanced content.

03

GHK-Cu (Copper Peptide) — Skin, Collagen & Aging

Anti-Aging / Skin

GHK-Cu is a naturally occurring tripeptide (Gly-His-Lys) that declines significantly with age. It has one of the most validated cosmetic peptide evidence bases with actual human clinical data. The gene expression data (Pickart et al.) showing 32 modulated gene pathways is particularly powerful content material.

  1. PMC (Free)
    Read first

    The definitive gene expression paper. GHK-Cu at 0.01nM modulates 31.2% of genes involved in tissue remodeling. Read this first.

  2. Skin Regenerative and Anti-Cancer Actions of Copper Peptides

    Pickart, Margolina · MDPI Cosmetics, 2018

    MDPI (Open Access)
    Read first

    RCT data included: GHK-Cu reduced wrinkle volume 55.8% vs control, 32.8% depth reduction. Strong human-applicable data for content.

  3. GHK-Cu: Background, mechanisms, and research review

    Wikipedia synthesis citing Pickart 1973 onwards · Ongoing

    Wikipedia (reference map)
    Read third

    Use as a citation map only — follow each footnote to the original paper. Do not cite Wikipedia itself.

04

Khavinson Bioregulatory Peptides — Epitalon & Longevity

Longevity / Bioregulators

Khavinson bioregulators are genuinely underexplored in Western content — four decades of Russian geroscience that most creators haven't touched. The key nuance: the majority of evidence comes from a single research group (St. Petersburg Institute), which limits independence of replication. This is what makes critical engagement with this topic genuinely valuable content.

  1. Loti Labs (Free)
    Read first

    Best Western synthesis of the full bioregulator framework. Covers cytomaxes vs cytagens, telomerase data, and independence limitations.

  2. Epitalon Research Studies and Evidence

    Peptide Protocol Wiki · 2026

    PeptideProtocolWiki (Free)
    Read second

    Clinical data summary: 13.3% lifespan extension in aged rats, hTERT activation in fibroblasts. Notes all evidence from Khavinson group.

  3. PeptideGuide (Free)
    Read second

    Covers short plasma half-life vs prolonged downstream transcriptional effects. Useful mechanism framing for content.

  4. Khavinson VKh — Peptides and Ageing (primary source review)

    Khavinson VKh · Neuro Endocrinol Lett, 2002

    PubMed
    Read second

    Primary source from Khavinson himself. Read to understand the theoretical framework before reading secondary analyses.

05

TB-500 (Thymosin Beta-4 Fragment)

Tissue Repair

TB-500 is often conflated with full-length Thymosin Beta-4, but they are chemically distinct — TB-500 is the 17AA actin-binding domain fragment (Ac-LKKTETQ-OH), not the full 43AA protein. The clinical trial data that exists (corneal healing, venous ulcers) was generated with full-length Tβ4. This distinction is critical and underreported in content.

  1. Superpower (Free)
    Read first

    Best current overview. Clearly distinguishes TB-500 from full Tβ4, covers actin sequestration mechanism, and notes FDA 503A Category 2 status.

  2. GlobalRPH (Free)
    Read first

    Clinical pharmacist perspective. Covers actin sequestration → cell motility → angiogenesis pathway in accessible language.

  3. PubMed
    Read second

    Landmark cardiac progenitor cell study. Key data point for cardiomyocyte survival and angiogenesis following MI.

06

Glutathione — Bioavailability, Routes & Antioxidant Science

Antioxidant / Recovery

The central question for subcutaneous glutathione content is bioavailability by route: oral GSH has very poor systemic availability due to intestinal γ-glutamyltransferase hydrolysis, which is why subcutaneous and IV routes are superior. The science here is well-established but poorly communicated in consumer content.

  1. ScienceOpen (Free)
    Read first

    Core paper on why oral GSH fails: γ-glutamyltransferase hydrolysis in the GI tract. The biological barrier explanation.

  2. PMC (Free)
    Read first

    RCT comparing micellar vs standard oral GSH. Only micellar showed improved GSH/GSSG ratio. Good comparative framing.

  3. PMC (Free)
    Read second

    N-methylated GSH analogue showing 16.8x longer plasma half-life and 16.1x better oral bioavailability. Frontier research.

  4. PMC (Free)
    Read second

    Human RCT. Sublingual GSH showed significantly improved GSH/GSSG ratio vs oral. Relevant to subQ comparison framing.

07

IGF-1 LR3 — Anabolic Mechanisms & Muscle Science

Anabolic / Performance

IGF-1 LR3 is a 83AA modified analog of IGF-1 with two structural changes that extend half-life to 20–30 hours and reduce IGFBP binding. The PI3K/Akt/mTOR and MAPK/ERK cascades it activates are the same pathways stimulated by resistance training, making this mechanistically rich territory for a gym-focused audience.

  1. PMC (Free)
    Read first

    Peer-reviewed full mechanism review: PI3K/Akt → mTORC1 → S6K1/4E-BP1 pathway. The foundational paper for IGF-1 signaling.

  2. PMC (Free)
    Read second

    Connects IGF-1R signaling to androgen receptor cross-talk. Relevant for gym audience interested in hormonal interactions.

  3. Peptides Institute (Free)
    Read second

    Good synthesis of satellite cell activation, hyperplasia vs hypertrophy distinction, and half-life mechanism. Verify citations.

08

Analytical Science — HPLC, LC-MS & COA Interpretation

Quality Control / Opti Peptides

This section is directly relevant to Opti Peptides and the third-party testing differentiation model. Being able to read and explain what a COA actually means — what HPLC purity tells you, why you also need mass spec identity confirmation, what endotoxin limits matter — is a genuine moat in the RUO peptide space.

  1. Peptide Purity Testing: HPLC and Mass Spectrometry Explained

    CertaPeptides / Adrian Bunea · Medium, 2026

    Medium (Free)
    Read first

    Practical breakdown of red flags in COAs: no mass spec, broad peaks, mass deviation >0.5%, no lot number. Very usable for content.

  2. Biovera (Free)
    Read first

    Column selection, mobile phase composition, RUO compliance framework. Bridges practical and regulatory knowledge.

  3. ICH Q2(R2) Guideline: Validation of Analytical Procedures

    International Council for Harmonisation · 2023

    ICH (Free PDF)
    Read second

    The international standard for analytical method validation. Knowing this framework puts you above most RUO vendors.

  4. USP (Free PDF)
    Read third

    LAL endotoxin assay context and limits. Reference for understanding what Janoshik endotoxin testing is actually measuring.

09

Essential Databases & Tools

These are the primary sources you should be searching directly, rather than relying on secondary content. Primary Literature Databases → PubMed / NCBI — The reference standard. Search compound name + mechanism keyword. Always check PMC link for free full text. → bioRxiv (preprints) — Cutting edge, unreviewed. Treat as hypothesis-generating, not confirmed findings. → Google Scholar — Use 'Cited by' to find papers that built on or challenged a key study. → Cochrane Library — Meta-analyses with bias assessment. Go here for aggregated evidence on a topic. Peptide & Compound Databases → ChEMBL — Bioactivity data, clinical trial phase, pharmacokinetics. Search any peptide compound. → DrugBank — Mechanism of action, receptor targets, metabolic pathways. Very accessible interface. → UniProt — Protein/peptide sequences, biological function, known interactions. → PDB (Protein Data Bank) — 3D molecular structures. Useful for visualising receptor binding — can generate images for content. Analytical & Regulatory References → ICH Quality Guidelines — ICH Q2 (analytical validation), Q6 (specifications). The framework Janoshik uses. → USP General Chapters — Endotoxin limits, method compendials. → FDA Draft Guidance — Bulk Drug Substances — 503A and 503B category classifications. Relevant to regulatory positioning of RUO peptides.

10

Recommended Textbooks

These are the foundational texts. You don't need to read them cover to cover — use them as reference material when you encounter a concept in a paper you don't understand. Lehninger Principles of Biochemistry — Nelson & Cox The biochemistry standard. Chapters on protein structure, enzyme kinetics, and signal transduction are most relevant. Biochemistry (Stryer) — Berg, Tymoczko, Stryer More accessible than Lehninger. Good for receptor signaling and metabolic pathways. Goodman & Gilman's Pharmacological Basis of Therapeutics — Multiple editors Pharmacology bible. Receptor mechanisms, PK/PD principles, therapeutic categories including GLP-1 class agents. Peptide and Protein Drug Analysis — Reid (ed.) Directly relevant to Opti Peptides. Analytical methods, stability, characterisation. Molecular Biology of the Cell — Alberts et al. Cell biology fundamentals. Useful for understanding receptor signalling pathways in depth. All textbooks are available cheaply second-hand or via Library Genesis (libgen.is) as PDFs — standard in academic research communities.

11

Progress Tracker

Track what you've read below. Update as you work through the list. @ThePepEducator | Opti Peptides | June 2026

  1. 01

    Structural insights into triple agonism at GLP-1R, GIPR and GCGR manif…
    Read third

  2. Triple hormone receptor agonist retatrutide for metabolic dysfunction-…
    Read third

  3. The power of three: Retatrutide's role in modern obesity and diabetes …
    Read third

  4. Progression from single to triple agonists: semaglutide, tirzepatide, …
    Read third

  5. Phase 2 obesity trial — retatrutide primary results (TRIUMPH data)
    Read third

  6. 02

    Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeleta…
    Read third

  7. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic R…
    Read third

  8. Multifunctionality and Possible Medical Application of the BPC 157 Pep…
    Read third

  9. The promoting effect of BPC 157 on tendon healing: tendon outgrowth, c…
    Read third

  10. BPC-157 Enhances Growth Hormone Receptor Expression in Tendon Fibrobla…
    Read third

  11. 03

    Regenerative and Protective Actions of the GHK-Cu Peptide in the Light…
    Read third

  12. Skin Regenerative and Anti-Cancer Actions of Copper Peptides
    Read third

  13. GHK-Cu: Background, mechanisms, and research review
    Read third

  14. 04

    Khavinson Bioregulators: The Complete Research Guide (Epitalon, Pineal…
    Read third

  15. Epitalon Research Studies and Evidence
    Read third

  16. Epithalon (Epitalon) Peptide Guide: Telomerase Research and Anti-Aging…
    Read third

  17. Khavinson VKh — Peptides and Ageing (primary source review)
    Read third

  18. 05

    TB-500: A Synthetic Thymosin Beta-4 Actin-Binding Fragment — Full Rese…
    Read third

  19. BPC-157 and TB-500: Background, Indications, Efficacy, and Safety
    Read third

  20. Cardiac Repair via Thymosin Beta-4 (Bock-Marquette et al.)
    Read third

  21. 06

    Oral delivery of glutathione: antioxidant function, barriers and strat…
    Read third

  22. Targeted Metabolomic Assessment of Oral Glutathione Bioavailability an…
    Read third

  23. Enhancing Oral Bioavailability of Glutathione Using Innovative Analogu…
    Read third

  24. Comparative crossover study: NAC vs oral GSH vs sublingual GSH on oxid…
    Read third

  25. 07

    Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy…
    Read third

  26. Crucial role of androgen receptor in resistance training-induced hyper…
    Read third

  27. IGF-1 LR3 Research Profile — Mechanism, PI3K/Akt, Satellite Cells
    Read third

  28. 08

    Peptide Purity Testing: HPLC and Mass Spectrometry Explained
    Read third

  29. HPLC Analysis Methods for Peptide Characterization
    Read third

  30. ICH Q2(R2) Guideline: Validation of Analytical Procedures
    Read third

  31. USP <1> Injections and Implanted Drug Products — Endotoxin Limits
    Read third

08Evidence report

The under-covered compounds, and what their data actually supports.

22 compounds the mainstream channels skip — researched from primary literature. Most are real molecules with real mechanisms and wildly overstated human evidence; each entry separates the two.

Human clinical data

Real trials in people exist, often non-Western.

Mixed / partial human data

Some human work, incomplete or not independently replicated.

Preclinical only

Animal or cell data only — no human efficacy proof.

Very thin evidence

Little or no independent published data.

Cluster 1 — Mitochondrial & Metabolic

The most genuinely interesting frontier on the list. Several of these are 'exercise mimetics' — they activate the same pathways as training (AMPK, ERRα, PGC-1α). The hook for content is strong, but almost all efficacy data is in mice.

Cluster 2 — Neuro & Cognitive

This cluster has something rare in the peptide world: actual clinical approval — but in Russia, in Russian-language journals, rarely replicated in Western RCTs. That East/West evidence asymmetry is the entire story and a strong content frame.

Cluster 3 — The Distinctive Oddballs

Mechanistically unusual compounds that don't fit a tidy category — a senolytic, a cancer-pore-former, an anti-inflammatory tripeptide, an innate-repair peptide, and an antimicrobial. The most varied and visually interesting teardowns on the list.

Cluster 4 — Khavinson Bioregulators

Four decades of Russian geroscience (Prof. Vladimir Khavinson, St. Petersburg Institute of Bioregulation and Gerontology). Ultra-short 2–4 amino-acid peptides proposed to act as tissue-specific epigenetic regulators. The defining caveat applies to ALL of them: the overwhelming majority of evidence comes from a single research group, with limited independent Western replication.

Appendix — data-poor compounds

These appear on the price list but have so little independent published data that an honest entry is short by necessity. Including them transparently — and saying the evidence isn't there — is more credible than manufacturing depth.

P21 (P021)
Small CNTF-derived peptidergic compound studied preclinically for BDNF-mediated neurogenesis in Alzheimer's models. Almost no independent human data; not to be confused with the p21 protein.
Kisspeptin
Genuinely well-studied in REPRODUCTIVE endocrinology (KISS1/GPR54; triggers GnRH/LH pulses; real human IVF and fertility trials exist) — but the body-composition/libido framing common in peptide sales is not what the strong data supports. Worth a careful, accurate stand-alone piece rather than a thin entry.
Dermorphin
A potent opioid heptapeptide (originally from Phyllomedusa frog skin); ~1000x morphine potency at mu-opioid receptors. Notorious as an illicit racehorse doping agent. No legitimate human therapeutic data; flag the controlled-substance/abuse profile.
Adamax / Cartalax / Thymulin variants
Niche bioregulator-class items with minimal independent literature beyond originating-group reports.
MitoPrime / Klow / Glow / Coremend / illumineuro blends
Vendor-formulated multi-peptide blends (e.g. GHK-Cu+KPV+BPC, or bioregulator stacks). No blend has its own controlled trial — evidence is at best the sum of weak single-component data.

Documentation

Ask for the certificate, not the claim.

For lot numbers, certificates of analysis, lead times or bulk pricing on anything in the catalogue, message the trade line. We do not discuss use of these materials.